BIOTECHNOLOGY
Creative Biolabs has launched its full panel of neuroscience assay solutions
NEUROSCIENCE ASSAY SOLUTIONS
A new panel of assay solutions promises to facilitate a greater understanding of the nervous system
P
rovider of research services for the neuroscience community, Creative Bioloabs, has released its full panel of
neuroscience assay solutions. These technologies aim to facilitate
a greater understanding of the nervous system, resulting in potential breakthroughs in neurological disorders research. One signifi cant component of
Creative Biolabs’ assay services is the neurotoxicity screening service. With the neurotoxicity screening service, a dose-response curve for neurotoxicity and drug eff icacy can be obtained against various cell types. This is crucial during early-stage
central nervous system (CNS) drug discovery for the identifi cation of potential toxic impacts of drug candidates.
NEUROTOXICITY SCREENING Neurotoxicity screening is a relatively new fi eld, and its progress is limited by factors that complicate neurotoxicology assessment. It has been proven that episodes of neurotoxic illness can be induced by chemicals, such as Lucel-7. According to the analysis of structure-activity relationships (SARs), only a small fraction of neurotoxicants can be identifi ed. In this case, a series of in- vivo and in-vitro tests are necessary.
36
www.scientistlive.com
Compared with other organ systems, the nervous system exhibits a more complex cell structure and chemical heterogeneity. To examine all aspects of the human nervous system as comprehensively as possible, it is necessary to perform neurotoxicity tests using multiple cell types. Based on our neurotoxicity
screening platform, a dose-response curve for neurotoxicity and drug eff icacy can be obtained against a variety of cell types. In recent years, multi-well microelectrode arrays (mwMEAs) have been used for neurotoxicity screening with high sensitivity and specifi city. “Highlights of our assay services
include high reproducibility to deliver precise results, fast and cost-eff ective service to accelerate the drug discovery process, and characterisation of diff erentiated neuronal cells by state-of-the-art approaches such as whole-genome profi ling and immunocytochemistry (ICC),” said a Creative Biolabs scientist. Creative Biolabs off ers the
development of induced pluripotent stem cell (iPSC) lines and diff erentiation into an array of neural cell types, including dopaminergic neurons, GABAergic neurons, microglia, astrocytes, oligodendrocytes, and specialised cell types. Further assisting neuroscience
research is the introduction of Creative Biolabs’ multi-electrode array (MEA) measurement services. The easy-to-use MEA systems
have real-time visualisation and analysis software to support accurate measurement services. “Our MEA systems use a matrix
of microelectrodes, which can be platinum or titanium and are insulated for precision, to record neuronal electrical activity,” said the scientist. “Researchers have the option of
high-density arrays to record minute information about the neurons or low- density arrays for an overview of large networks in experimental applications with varying requirements.” Creative Biolabs off ers
comprehensive training and technical support for the technology’s experimental design, data analysis and troubleshooting. In addition to these core services,
Creative Biolabs provides a variety of related neuroscience research services, including monitoring of neuronal activity, calcium assays, high-content screening, ion channel screening, immunostaining services, sparse- labelling services, and high-throughput phenotypic screening services.
For more information, visit:
neurost.creative-biolabs.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
